DexCom Stock: Is Wall Street Bullish or Bearish?

Company Overview - DexCom, Inc. (DXCM) is a leading medical-device company specializing in continuous glucose monitoring (CGM) systems for diabetes management, with a market capitalization of approximately $23.2 billion [1] Stock Performance - Over the past 52 weeks, DXCM stock has declined by 19.8%, while the S&P 500 Index has increased by 14.5%. Year-to-date, the stock is down 23.4%, compared to a 16.5% rise in the S&P 500 [2] - DexCom's shares have also underperformed the Health Care Select Sector SPDR Fund, which returned 3.8% over the past 52 weeks and 11.1% year-to-date [3] Earnings and Outlook - The company reported a solid third-quarter earnings performance, beating estimates; however, management's outlook indicated that growth in 2026 may be slightly below market expectations, raising concerns among investors [4] - For the fiscal year ending December 2025, analysts project DexCom's earnings per share (EPS) to grow by 26.2% year-over-year to $2.07. The company's earnings surprise history is mixed, with two beats and two misses in the last four quarters [5] Analyst Ratings - Among 28 analysts covering DexCom, the consensus rating is a "Strong Buy," consisting of 21 "Strong Buys," one "Moderate Buy," and six "Hold" ratings [6] - The consensus rating has become slightly more bullish compared to three months ago, when there were 20 "Strong Buy" ratings [7] Price Targets - Bernstein SocGen Group recently lowered its price target for DexCom from $98 to $84 while maintaining an "Outperform" rating. The mean price target of $87.38 suggests a potential upside of 46.7% from current levels, while the highest target of $125 indicates a possible rally of 109.7% [7]